SCHEMBL30135868

SCHEMBL30135868

Cn1nc(N2CCC(=O)NC2=O)c2ccc(N3CCC(CN4CCC5(CC4)CC(NC(=O)OCc4ccccc4)C5)CC3)cc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 3/20 0.43
CRBN Q96SW2 3/20 0.43
ENPP2 Q13822 2/20 0.38
ATXN2 Q99700 2/20 0.38
HTR1A P08908 1/20 0.36
DRD2 P14416 1/20 0.36
HTR2A P28223 1/20 0.36
CHRM4 P08173 3/20 0.35
VCP P55072 1/20 0.35
HTR3A P46098 2/20 0.35
TMEM97 Q5BJF2 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
SYK P43405 1/20 0.33
ROCK2 O75116 1/20 0.33
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25819509 0.86 CHRM4 (0.44) DDB1CRBNENPP2ATXN2CHRM4
SCHEMBL30135969 0.85 CHRM4 (0.42) DDB1CRBNENPP2ATXN2CHRM4
SCHEMBL30135966 0.82 CRBN (0.55) DDB1CRBN
SCHEMBL30965642 0.78 CHRM4 (0.44) ENPP2ATXN2CHRM4MEN1KMT2A
SCHEMBL30915053 0.78 DDB1 (0.52) DDB1CRBNHTR1AHTR2ATMEM97
SCHEMBL25819521 0.77 CHRM4 (0.45) ENPP2ATXN2CHRM4VCPTMEM97
SCHEMBL25819512 0.77 CHRM4 (0.48) ENPP2ATXN2CHRM4SYK
SCHEMBL25589046 0.76 CRBN (0.62) DDB1CRBNHTR1AADORA2AADORA1
SCHEMBL25589986 0.76 CRBN (0.62) DDB1CRBNHTR1AADORA2AADORA1
SCHEMBL30135714 0.76 ENPP2 (0.38) DDB1CRBNENPP2ATXN2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250101025-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2025-03-27 US disclosed
EP-4384521-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND Uppthera, Inc. (KR) 2024-06-19 EP disclosed
WO-2023018237-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-02-16 WO disclosed
WO-2023017446-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250101025-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 DDB1 132/4885CRBN 2136/4885ENPP2 1565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.